NCT01841944

Brief Summary

The aim of the present study is to investigate the possible effects of supplementation with 1.8 g/day of n-3 polyunsaturated fatty acids on cardiovascular morbidity and mortality during a follow-up period of 2 years in an elderly population after having experienced an acute myocardial infarction. The hypothesis is that this supplementation on top of modern therapy will reduce the combined cardiovascular end-point of death, non-fatal myocardial infarction, stroke, revascularizations or hospitalization for new or worsened heart failure with at least 30%.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,027

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2012

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 16, 2013

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 29, 2013

Completed
7.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 26, 2020

Completed
Last Updated

August 19, 2020

Status Verified

August 1, 2020

Enrollment Period

7.7 years

First QC Date

April 16, 2013

Last Update Submit

August 18, 2020

Conditions

Keywords

Fatty Acids, Omega-3AgedMyocardial Infarction

Outcome Measures

Primary Outcomes (1)

  • Combined total mortality, first event of non-fatal myocardial infarction, stroke, revascularization or hospital admission for new or worsened heart failure.

    24months

Secondary Outcomes (1)

  • Occurence of new onset atrial fibrillation

    24months

Study Arms (2)

Pikasol

ACTIVE COMPARATOR

Pikasol®, 3 capsules (1.8 g EPA+DHA)/day

Drug: Pikasol

Corn oil

PLACEBO COMPARATOR

3x capsules of corn oil pr day

Other: Corn oil

Interventions

Pikasol®, 3 capsules (1.8 g EPA+DHA)/day

Also known as: omega-3, polyunsaturated fatty acids
Pikasol

Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer

Corn oil

Eligibility Criteria

Age70 Years - 82 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Patients with acute myocardial infarction discharged from hospital alive

You may not qualify if:

  • Being part of another randomized trial
  • Documented intolerance for omega-3 fatty acids
  • Additional disease state that is thought to be incompatible with compliance to the study drugs
  • Additional disease state thought to reduce survival for the follow-up time of 2 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Asker and Bærum Hospital

Rud, Bærum, 1309, Norway

Location

Akershus university hospital HF

Lørenskog, 1478, Norway

Location

Oslo University Hospital(Ullevaal)

Oslo, 0424, Norway

Location

Stavanger University Hospital

Stavanger, Norway

Location

Related Publications (5)

  • Chiva-Blanch G, Bratseth V, Laake K, Arnesen H, Solheim S, Schmidt EB, Badimon L, Seljeflot I. One year of omega 3 polyunsaturated fatty acid supplementation does not reduce circulating prothrombotic microvesicles in elderly subjects after suffering a myocardial infarction. Clin Nutr. 2021 Dec;40(12):5674-5677. doi: 10.1016/j.clnu.2021.10.007. Epub 2021 Oct 20.

  • Kalstad AA, Myhre PL, Laake K, Opstad TB, Tveit A, Solheim S, Arnesen H, Seljeflot I. Biomarkers of ageing and cardiac remodeling are associated with atrial fibrillation. Scand Cardiovasc J. 2021 Aug;55(4):213-219. doi: 10.1080/14017431.2021.1889653. Epub 2021 Mar 2.

  • Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H; OMEMI Investigators. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation. 2021 Feb 9;143(6):528-539. doi: 10.1161/CIRCULATIONAHA.120.052209. Epub 2020 Nov 15.

  • Kalstad AA, Tveit S, Myhre PL, Laake K, Opstad TB, Tveit A, Schmidt EB, Solheim S, Arnesen H, Seljeflot I. Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients. BMC Geriatr. 2019 Dec 27;19(1):376. doi: 10.1186/s12877-019-1383-9.

  • Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, Tveit A, Arnesen H, Solheim S. Effects of omega3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. BMC Geriatr. 2014 Jun 13;14:74. doi: 10.1186/1471-2318-14-74.

MeSH Terms

Conditions

Myocardial InfarctionHeart FailureAtrial Fibrillation

Interventions

PikasolDocosahexaenoic AcidsFatty Acids, UnsaturatedCorn Oil

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosisArrhythmias, Cardiac

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsFatty AcidsFish OilsOilsFats, UnsaturatedPlant OilsPlant PreparationsBiological ProductsComplex MixturesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Harald Arnesen, MD Phd

    Center for Clinical Heart Research

    STUDY CHAIR
  • Svein Solheim, MD phd

    Center for Clinical Heart Research

    STUDY DIRECTOR
  • Ingebjørg Seljeflot, Phd

    Center for Clinical Heart Research

    STUDY DIRECTOR
  • Kristian Laake, MD

    Center for Clinical Heart Research

    PRINCIPAL INVESTIGATOR
  • Peder Myhre, MD

    Center for Clinical Heart Research

    PRINCIPAL INVESTIGATOR
  • Are A Kalstad, MD

    Center for Clinical Heart Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

April 16, 2013

First Posted

April 29, 2013

Study Start

November 1, 2012

Primary Completion

June 26, 2020

Study Completion

June 26, 2020

Last Updated

August 19, 2020

Record last verified: 2020-08

Locations